Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score ® Test from a US Societal Perspective.
Vladislav BerdunovGebra Cuyun CarterEwan LawsRoger LuoChristy A RussellSara CampbellYara AbdouJeremy ForcePublished in: ClinicoEconomics and outcomes research : CEOR (2024)
Adjuvant chemotherapy decisions based on the RS result led to more life year gains and lower healthcare costs (dominant) compared to using clinical-pathological risk factors alone among patients with HR+/HER2- N0 and N1 early-stage breast cancer.